Internal restructuring
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Chemicals And Chemical Products
20 - Manufacture of chemicals and chemical products

400 jobs
Number of planned job losses
Job loss
Announcement Date
18 December 2004
Employment effect (start)
1 January 2005
Foreseen end date


DSM is to restructure its money-losing anti-infectives business, closing capacity in Europe and increasing output in Asia. 400 jobs or 13% of the business's total will go. Weak markets, the decline of the dollar, and strong growth in Asia are cited as main reasons for the restructuring. A plant at Delft and a plant at Geleen, the Netherlands, will close in 2005. A joint venture with Glaxo SmithKline at Irvine, UK is to end in 2005. DSM is to expand and upgrade production at its anti-infectives plant at Toansa, India, and at its joint venture's at Harbin, Zhang Jiakou, and Zibo, China. Antibiotics markets in China and India continue to grow. About 250 of the job cuts will be in the Netherlands. The restructuring should mean annualized cost savings of tens of millions of euros within two years.


  • 18 December 2004: Haagsche Courant


Eurofound (2004), DSM Anti-Infectives, Internal restructuring in World, factsheet number 60968, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/60968.